BR112022026747A2 - Métodos de tratamento do distúrbio do espectro da neuromielite óptica - Google Patents
Métodos de tratamento do distúrbio do espectro da neuromielite ópticaInfo
- Publication number
- BR112022026747A2 BR112022026747A2 BR112022026747A BR112022026747A BR112022026747A2 BR 112022026747 A2 BR112022026747 A2 BR 112022026747A2 BR 112022026747 A BR112022026747 A BR 112022026747A BR 112022026747 A BR112022026747 A BR 112022026747A BR 112022026747 A2 BR112022026747 A2 BR 112022026747A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- treatment
- nmosd
- spectrum disorders
- neuromyelitis
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 238000001228 spectrum Methods 0.000 title abstract 2
- 208000029067 Neuromyelitis optica spectrum disease Diseases 0.000 abstract 4
- 208000008795 neuromyelitis optica Diseases 0.000 abstract 4
- 101800000263 Acidic protein Proteins 0.000 abstract 1
- 230000009266 disease activity Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002518 glial effect Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046133P | 2020-06-30 | 2020-06-30 | |
| US202063052093P | 2020-07-15 | 2020-07-15 | |
| US202063071092P | 2020-08-27 | 2020-08-27 | |
| PCT/US2021/039911 WO2022006283A2 (en) | 2020-06-30 | 2021-06-30 | Methods of treating neuromyelitis optica spectrum disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022026747A2 true BR112022026747A2 (pt) | 2023-01-24 |
Family
ID=79321915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022026747A BR112022026747A2 (pt) | 2020-06-30 | 2021-06-30 | Métodos de tratamento do distúrbio do espectro da neuromielite óptica |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230406928A1 (enExample) |
| EP (1) | EP4172211A4 (enExample) |
| JP (1) | JP2023534916A (enExample) |
| KR (1) | KR20230030642A (enExample) |
| CN (1) | CN116234571A (enExample) |
| AU (1) | AU2021299307A1 (enExample) |
| BR (1) | BR112022026747A2 (enExample) |
| CA (1) | CA3178954A1 (enExample) |
| IL (1) | IL299381A (enExample) |
| MX (1) | MX2022016236A (enExample) |
| WO (1) | WO2022006283A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230097118A (ko) * | 2020-10-29 | 2023-06-30 | 비엘라 바이오, 인크. | 자가면역 질환을 치료하기 위한 항-cd19 항체의 사용 |
| CN117797245A (zh) * | 2023-12-29 | 2024-04-02 | 广州赛莱拉干细胞科技股份有限公司 | 人乳脂球表皮生长因子8用于制备治疗视神经脊髓炎谱系疾病药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021020924A2 (pt) * | 2019-04-24 | 2022-04-19 | Viela Bio Inc | Uso de um anticorpo anti-cd19 para tratar doença autoimune |
| KR20230097118A (ko) * | 2020-10-29 | 2023-06-30 | 비엘라 바이오, 인크. | 자가면역 질환을 치료하기 위한 항-cd19 항체의 사용 |
-
2021
- 2021-06-30 KR KR1020237002980A patent/KR20230030642A/ko active Pending
- 2021-06-30 EP EP21834411.7A patent/EP4172211A4/en active Pending
- 2021-06-30 CA CA3178954A patent/CA3178954A1/en active Pending
- 2021-06-30 JP JP2022581408A patent/JP2023534916A/ja active Pending
- 2021-06-30 AU AU2021299307A patent/AU2021299307A1/en active Pending
- 2021-06-30 MX MX2022016236A patent/MX2022016236A/es unknown
- 2021-06-30 IL IL299381A patent/IL299381A/en unknown
- 2021-06-30 CN CN202180046409.5A patent/CN116234571A/zh active Pending
- 2021-06-30 WO PCT/US2021/039911 patent/WO2022006283A2/en not_active Ceased
- 2021-06-30 BR BR112022026747A patent/BR112022026747A2/pt unknown
-
2022
- 2022-12-28 US US18/147,287 patent/US20230406928A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022006283A2 (en) | 2022-01-06 |
| AU2021299307A1 (en) | 2022-12-22 |
| US20230406928A1 (en) | 2023-12-21 |
| MX2022016236A (es) | 2023-03-29 |
| EP4172211A2 (en) | 2023-05-03 |
| JP2023534916A (ja) | 2023-08-15 |
| WO2022006283A3 (en) | 2022-02-03 |
| EP4172211A4 (en) | 2024-07-10 |
| CA3178954A1 (en) | 2022-01-06 |
| IL299381A (en) | 2023-02-01 |
| KR20230030642A (ko) | 2023-03-06 |
| CN116234571A (zh) | 2023-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022026747A2 (pt) | Métodos de tratamento do distúrbio do espectro da neuromielite óptica | |
| BRPI0515884A (pt) | métodos de diagnóstico e tratamento de complicações da gravidez | |
| BRPI0507442B8 (pt) | método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia | |
| AR080564A1 (es) | Metodos para el tratamiento o prevencion de enfermedades asociadas al receptor del factor de crecimiento epidermico humano-3 (her-3) | |
| CY1119122T1 (el) | Θεραπευτικη αναπληρωση και εμπλουτισμος της λιπανσεως της οφθαλμικης επιφανειας | |
| Puig et al. | Processing speed and executive functions predict real-world everyday living skills in adolescents with early-onset schizophrenia | |
| EA201490697A1 (ru) | Белки с двойной функцией для лечения метаболических расстройств | |
| BR112013000027A2 (pt) | tratamento de distúrbios cognitivos | |
| BRPI0910993A2 (pt) | técnica de administração na linha de sutura usando toxinas botulínicas | |
| EA201070553A1 (ru) | Антитела к гепцидину и варианты их применения | |
| ATE543427T1 (de) | Verbesserung von oder im zusammenhang mit scanning-ophthalmoskopien | |
| BR112021024634A2 (pt) | Método de tratamento ou prevenção de um distúrbio, doença ou condição aliviada pela estimulação ou modulação da expressão de colágeno | |
| BR112021015222A2 (pt) | Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1 | |
| BR112021021141A2 (pt) | Método para modular estrutura glicocalyx endotelial | |
| BR112022008886A2 (pt) | Diagnóstico de transtornos de humor usando biomarcadores de edição de rna do sangue | |
| Peters et al. | Inflammation, depressive symptoms, and emotion perception in adolescence | |
| Simhadri et al. | Dysregulation of LIMK‐1/cofilin‐1 pathway: a possible basis for alteration of neuronal morphology in experimental cerebral malaria | |
| BR112019022912A2 (pt) | Métodos e composições para tratar doenças oculares alérgicas | |
| BR112022023928A2 (pt) | Uso de canabidiol para o tratamento do transtorno do espectro autista | |
| da Silva et al. | Effects of cognitive-behavioral therapy on neurotrophic factors in patients with major depressive disorder | |
| Ziegler et al. | Overexpression of cutaneous mitochondrial superoxide dismutase in recent-onset type 2 diabetes | |
| BRPI0607507A2 (pt) | método in vitro para a identificação de compostos para tratamento do cáncer | |
| Park et al. | Myosin heavy chain isoform expression in human extraocular muscles: longitudinal variation and patterns of expression in global and orbital layers | |
| EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ | |
| BR112023023558A2 (pt) | Anticorpos anti-tmprss6 e usos dos mesmos |